Core Viewpoint - Company is rated "Buy" by Guotai Junan Securities, highlighting its position as a leading global preclinical CRO and biotechnology firm with strong technical barriers and stable revenue growth from preclinical products and services [1] Group 1: Revenue Growth and Business Model - Preclinical products and services are the foundation of the company's business, with revenue growing rapidly due to leading gene editing technologies and a high-quality humanized antibody mouse platform [2] - Sales of model animals increased from 66 million yuan in 2021 to 389 million yuan in 2024, with a CAGR exceeding 50% [2] - The company has established long-term partnerships with over 950 global partners, completing more than 6,350 drug evaluation projects, maintaining a clinical preclinical pharmacology customer retention rate above 60% [2] Group 2: Antibody Development and Growth Engines - The "Thousand Mice and Ten Thousand Antibodies" plan is entering a monetization phase, with antibody development and licensing becoming strong growth drivers [2] - Revenue from antibody development increased from 127 million yuan in 2022 to 318 million yuan in 2024, with a CAGR of 58% and a gross margin exceeding 90% in 2024 [2] - The million-level antibody sequence library provides high-quality antibody molecules for global partners and maximizes technical value through various models such as licensing and collaborative development [2]